Phase 3 study of durvalumab (MEDI4736) alone or in combination with tremelimumab versus standard of care (SoC) in platinum-resistant recurrent ormetastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): EAGLE

被引：0
|
作者：
Licitra, L. [1 ]
Even, C. [2 ]
Haddad, R. [3 ]
Tahara, M. [4 ]
Goswami, T. [5 ]
Franks, A. [6 ]
Emeribe, U. [7 ]
Jarkowski, A., III [5 ]
Melillo, G. [7 ]
Ferris, R. L. [8 ,9 ]
机构：
[1] Fdn IRCCS Inst Nazl Tumori, Head & Neck Canc Med Oncol Unit, Milan, Italy
[2] Inst Gustave Roussy, Head & Neck Oncol, Villejuif, France
[3] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[4] Natl Canc Ctr Hosp East, Head & Neck Med Oncol, Kashiwa, Chiba, Japan
[5] AstraZeneca, Immunooncol GMD, Gaithersburg, MD USA
[6] AstraZeneca, Clin Dev, Immunooncol, Gaithersburg, MD USA
[7] AstraZeneca, Global Med Dev, Gaithersburg, MD USA
[8] Univ Pittsburgh, Inst Canc, Dept Otolaryngol, Pittsburgh, PA USA
[9] Univ Pittsburgh, Inst Canc, Canc Immunol Program, Pittsburgh, PA USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
341TiP
引用
收藏
页码：101 / 101
页数：1
相关论文
共 50 条
  • [1] Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
    Siu, Lillian L.
    Papadopoulos, Kyriakos P.
    Tsai, Frank Yung-Chin
    Hansen, Aaron Richard
    Robbins, Paul B.
    Li, Xia
    Lai, Dominic W.
    Blake-Haskins, John A.
    Fury, Matthew G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
    Jove, M.
    Brana, I.
    Oliva Bernal, M.
    Hernando-Calvo, A.
    Erasun Lecuona, C.
    Assaf Pastrana, J. D.
    Bazan Peregrino, M.
    Mato-Berciano, A.
    Maliandi, M. V.
    Torres-Manjon, S.
    Martinez De Villareal, J.
    Real, F. X.
    Nuciforo, P. G.
    Alemany, R.
    Capella, G.
    Blasi, E.
    Blasco, C.
    Cascallo Piqueras, M.
    Mesia Nin, R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1112 - S1112
  • [3] A Phase 2, multicenter, single-arm, global study of MEDI4736 monotherapy in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): HAWK (NCT02207530).
    Zandberg, Dan Paul
    Jarkowski, Anthony
    Emeribe, Ugochi A.
    Goswami, Trishna
    Melillo, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC
    Mok, T.
    Schmidt, P.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, K.
    Martin, C.
    McIntosh, S.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S140 - S141
  • [5] DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)
    Park, S. H.
    Castellano, D.
    Petrylak, D. P.
    Galsky, M. D.
    van der Heijden, M. S.
    Loriot, Y.
    Ogawa, O.
    Su, W-P.
    Huang, W.
    Levin, W.
    Ferro, S.
    Ben, Y.
    Bellmunt, J.
    Powles, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [6] Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE
    Mok, T.
    Schmid, P.
    de Castro, G., Jr.
    Syrigos, K.
    Martin, C.
    Yamamoto, N.
    Aren, O.
    Arrieta, O.
    Gottfried, M.
    Jazieh, A. R.
    Ramlau, R.
    Timcheva, C.
    Trani, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] RAPTOR, the global phase II, III clinical development program of the PD-L1 inhibitor Durvalumab (MEDI4736) in 2nd-line recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) - A German update on the HAWK, EAGLE and CONDOR trials
    Ruessel, J.
    von Einem, J.
    Keilholz, U.
    Dietz, A.
    Gruenewald, V
    Maschmeyer, G.
    Kasper, S.
    Rupprecht, M.
    Sasse, B.
    Melillo, G.
    Krauss, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 173 - 174
  • [8] Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
    Ferris, R. L.
    Haddad, R.
    Even, C.
    Tahara, M.
    Dvorkin, M.
    Ciuleanu, T. E.
    Clement, P. M.
    Mesia, R.
    Kutukova, S.
    Zholudeva, L.
    Daste, A.
    Caballero-Daroqui, J.
    Keam, B.
    Vynnychenko, I.
    Lafond, C.
    Shetty, J.
    Mann, H.
    Fan, J.
    Wildsmith, S.
    Morsli, N.
    Fayette, J.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2020, 31 (07) : 942 - 950
  • [9] A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE
    Powles, Thomas
    Galsky, Matt D.
    Castellano, Daniel
    Van Der Heijden, Michiel Simon
    Petrylak, Daniel Peter
    Armstrong, Jon
    Belli, Riccardo
    Ferro, Salvatore
    Ben, Yong
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345